Legend Biotech is a holding company. Through its subsidiaries, Co. is a clinical-stage biopharmaceutical company engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Co.'s primary product candidate, ciltacabtagene autoleucel, or cilta-cel (referred to as LCAR- B38M for purposes of its LEGEND-2 trial), is a chimeric antigen receptor T cell (CAR-T) therapy it is jointly developing with its partner, Janssen Biotech, Inc. for the treatment of multiple myeloma. In addition to cilta-cel, Co. has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma. The LEGN stock yearly return is shown above.
The yearly return on the LEGN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the LEGN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|